In medical news, an experimental new drug called donanemab has slowed the progression of Alzheimer’s disease in patients by about 35%, when used in the early stages of the disease. That makes the drug at least as effective as Leqembi, another monoclonal antibody treatment against Alzheimer’s that won FDA approval earlier this month. Drugmaker Eli Lilly hasn’t said how much donanemab would cost if it wins regulatory approval, but a year’s treatment of Leqembi has been priced at more than $26,000 in the U.S.